Literature DB >> 6460704

Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2.

B M Vose, G D Bonnard.   

Abstract

Peripheral blood lymphocytes of cancer patients were sensitized in vitro to autologous tumour cells in mixed lymphocyte-tumour culture (MLTC). Blast cells were isolated on discontinuous Percoll gradients from MLTC which showed significant stimulation of [3H]-thymidine incorporation. Cultured T cells (CTC) were derived from these blasts by growth in conditioned medium containing interleukin-2 (IL-2) and maintained for up to 51 days by repeated feeding with IL-2 and in some cases by addition of irradiated allogeneic blood mononuclear cells as "fillers". These cultures showed specific cytotoxic reactivity against autologous tumour and in only a few cases was natural killing (NK) of K562 cells apparent. Restimulation of CTC with tumour was measured in primed lymphocyte test (PLT). Increased uptake of [3H]-thymidine was found upon stimulation by autologous tumour and allogeneic tumour of the same site and histology but there was no response to non-related tumours or to a panel of allogeneic lymphocytes. No sensitization to autologous HLA-D/DR could be detected by restimulation or cytotoxicity against monocytes in the majority of cases. These data suggest that, by careful selection of sensitised blasts from MLTC, it is possible to obtain CTC with both helper (proliferative) and cytotoxic T cells and that such CTC have specific reactivity against tumour cells. These cellular reagents will be useful in defining the antigenicity of human neoplasms and possibly in therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460704     DOI: 10.1002/ijc.2910290107

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Killer cells induced by stimulation with allogeneic tumor cells and subsequent culture with recombinant interleukin-2.

Authors:  T Fukiage; H Murakami; M Eura; T Ikawa; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 2.  Retinoids and the control of growth/death decisions in human neuroblastoma cell lines.

Authors:  G Melino; C J Thiele; R A Knight; M Piacentini
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 3.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

Review 4.  Direct identification of tumor-associated peptide antigens.

Authors:  V H Engelhard
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Mitogenic stimulation of human tumor-infiltrating lymphocytes by secreted factor(s) from human tumor cell lines.

Authors:  B S Packard
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures.

Authors:  P Hersey; M MacDonald; S Schibeci; C Burns
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission.

Authors:  R Somasundaram; S G Rao; S H Advani; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence.

Authors:  H Koho; S Paulie; H Ben-Aissa; I Jónsdóttir; Y Hansson; M L Lundblad; P Perlmann
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  The role of major histocompatibility complex expression on head and neck cancer cells in the induction of autologous cytotoxic T lymphocytes.

Authors:  K Chikamatsu; M Eura; H Matsuoka; H Murakami; T Fukiage; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

Review 10.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.